Three-Time Winner: Dr. Mark Souweidane
Extends His Fight Against DIPG
In a new milestone in the fight against DIPG, Dr. Mark Souweidane this week performed a direct infusion of a cancer-fighting drug into the brain of a young patient — for the third time. The child was the first ever to receive three infusions, all at the highest dose level in the trial.
The six–year–old, who was diagnosed with DIPG in January of this year, joined Dr. Souweidane´s clinical trial in June, when he was treated with an interstitial infusion (also called convection–enhanced delivery, or CED) of a drug intended to stop DIPG´s usual relentless progression. By delivering the drug directly into the tumor site, Dr. Souweidane avoids the difficulty of getting that drug across the defensive blood-brain barrier. (See more about the trial.) The child received a second infusion in July, and then was treated for a third time this week.
“He´s recovering beautifully,” said Dr. Souweidane of the patient. “An MRI immediately after the infusion showed excellent drug distribution in the brain stem and no unexpected findings. More importantly, he is himself. When I spoke to him the day after his treatment and asked what he wanted to be for Halloween, he told me he wanted to be Darth Sidious."
Several children have been treated twice in the trial, but Dr. Souweidane says this child was doing very well, with no disease progression, which boded well for a third treatment. The patient’s parents were also persistent in their drive to have their child treated again.
“They´re already asking about a fourth treatment,” says Dr. Souweidane. The first phase of the trial ended this summer, when the 27th and final patient was infused for the first time, but the FDA has approved repeated treatments as an extension of the trial.
It´s too soon yet to tell whether and how the repeated infusions will affect the ultimate course of this uniformly fatal disease. But Dr. Souweidane says there’s no reason why other children who were treated already, even at the maximum dose level, can´t be treated again. He´'s energized by these latest treatments, and is already looking ahead to the future.
“Each of the three infusions contained the seventh and highest dose level tested in this trial,” says Dr. Souweidane. “The ability to tolerate three infusions in such a short time, and of the maximum dose, paves the way for one of the possible next steps in this avenue of investigation, which could be to implant an infusion system to deliver the drug without repeated surgery.”
Whatever the next steps are, Dr. Souweidane promises to be at the forefront of the research.
Read the blog of Three-Time Winner: Dr. Souweidane Extends His Fight Against DIPG, click the link below
Dr. Souweidane Treats Final Patient in
Groundbreaking DIPG Clinical Trial
Dr. Mark Souweidane today treated the final patient in his Phase I clinical trial of convection-enhanced delivery (CED) for diffuse intrinsic pontine glioma (DIPG). The trial, which had enrolled 31 patients over the past four years, was designed to test the safety of CED as a means of delivering a cancer-fighting drug directly to the site of a DIPG tumor. (More about the DIPG trial.)
The trial received FDA approval in late 2011, and the first patient was treated in May 2012. (Read “Cheering for Caitlin,” a profile of the first patient.) Since then, 30 children have received infusions of a therapeutic agent called 124I-8H9, which consists of the 8H9 antibody (produced by mice and effective against many kinds of tumors) combined with the radioactive substance 124I. The dosage of the drug was increased over the course of the trial, also testing safety, but no dose-limiting side effects occurred in any patient.
The infusions, which were done at Memorial Sloan Kettering Cancer Center, were able to deliver the drug directly to the brain stem tumor and were not blocked by the body’s protective blood-brain barrier, which normally prevents chemotherapy drugs from crossing from the bloodstream into the brain in sufficient concentrations to attack a tumor. In this trial, Dr. Souweidane was able to achieve concentrations of 1,000 times or more than what can be achieved with IV chemotherapy. He was also able to design and test new ways to measure those concentrations at the tumor site and monitor how long the drug stayed in the tumor.
Dr. Souweidane and his team will spend the next several months evaluating the data and preparing the results for publication. In the meantime, researchers in the Children’s Brain Tumor Project laboratory have been working to pave the road for the next stages of the trial. Other drugs and drug combinations are being tested to determine what the best agents are to infuse, and at what dose levels. DIPG cell lines are also being grown in the lab, providing a rich source of information about how the tumor mutates over time and responds to different treatments in vitro as well as in animal models. (More about the Children’s Brain Tumor Project.)
Read the blog post written by Dr. Souweidane after he treated the final patient in the trial, click the link below
Minnesota Boy with D.I.P.G. meets his favorite
Power Ranger in California thanks to Little Kernel Popcorn Company & Cristian Rivera Foundation
Minnesota Boy with D.I.P.G. meets his favorite
Power Ranger in California thanks to Little Kernel Popcorn Company & Cristian Rivera Foundation
At The Cristian Rivera Foundation, our primary goal is to assist in finding a cure for Diffuse Intrinsic Pontine Glioma. Our Foundation also plays a critical role in supporting families that are impacted by D.I.P.G. By pulling together all of our resources to make dreams come true.
Such is the case when the founder of the Cristian Rivera Foundation,
John Gungie Rivera, learned about Allen Xiong's wish to meet the blue Power Ranger.
Allen is an 8 year old boy who was diagnosed with D.I.P.G. Just like most children his age, he loves The Power Rangers and his dream was to meet his favorite Power Ranger- the Blue Power Ranger. John contacted the CEO of The Little Kernel Popcorn Company, Andy Epstein. He also contacted Craig Serra who also serves as a board of directors for The Cristian Rivera Foundation & "JOINED FORCES" with Robert Vazquez, a Cristian Rivera committee member, and Like the Power Rangers, they all "JUMPED INTO ACTION" and started the process of making Allen's wish come true.
This past weekend The Cristian Rivera Foundation and
The Little Kernel company fulfilled Allen's wish when he came
FACE TO FACE with "Yoshi", the talented actor who plays the
Blue Power Ranger at the Pasadena Morphicon Power Ranger Convention.
After Allen met his favorite Blue Power Ranger here is what his family said- "Thank you CRF... Allen was sooo happy today when he met with Yoshi the Blue Dino Power Ranger... It made him speechless... He didn´t know how to speak anymore lol he was so shy and nervous that he forgot how to talk or move lol... We saw him yesterday at the Q & A but didn´t meet him yet... I didn´t know who Yoshi is until Allen point him out and say mom he´s the blue Dino power ranger.. I asked him how he know? He´s not him his costume? Allen response was that you got to be a big fan to know lol... This boy is too smart for me... Thank you from the bottom of our heart for making this dream come true.. Love Allen and family ♥♥♥"
We at The Cristain Rivera Foundation & The Little Kernel Popcorn Company are "Full Steam Ahead" in finding a cure and fulfilling dreams! Spread the word, support & help us get closer to a cure.
Learn more at CristianRiveraFoundation.org
The mission of the Cristian Rivera Foundation is to help find the cure for the Pontine Glioma brain stem tumor.
What is DIPG (Diffuse Intrinsic Pontine Glioma)?
Diffuse Intrinsic Pontine Glioma or DIPG, is a Rare, Inoperable Brain Stem Tumor that predominantly affects children between the ages of 2 and 10. Only 200-300 cases are discovered in the United States each year and because there is no cure, it’s young victims only have an average of 3-18 months to live, after they’ve been diagnosed. There are NO SURVIVORS.
Who is The Cristian Rivera Foundation?
The Cristian Rivera Foundation is a 501 (c)(3) Non-Profit Organization that works tirelessly, in order to raise awareness and funds to one day put a STOP to this disease. The Cristian Rivera Foundation funds the work of Dr. Mark Souweidane of Weill Cornell Medical Center – Memorial Sloane (Kettering) Cancer Center and Dr. Oren Becher of Duke University. Both Doctors are conducting promising research and trails that have shown promising results. We are CLOSE to a CURE!
How Can You Help:
- Help us by making a Donation.
- Every Donation Big or Small, will help us achieve our goal.
- Help spread the word to your family, friends and Colleagues.
Thank You again and may this be the year we say goodbye to DIPG, (Diffuse Intrinsic Pontine Glioma), FOREVER!
The Cristian Rivera Foundation
John “Gungie” Rivera
(Founder of The Cristian Rivera Foundation & “Forever Cristian’s Daddy”)
Board of Directors of the Cristian Rivera Foundation:
Andy Epstein, Darlene Rodriguez and Craig Serra.
Committee Members of the Cristian Rivera Foundation:
Aldo Marin, Alex Garcia, Carlos Colon, Carlos Yepez, Dennis Rodriguez, Dolores Catania, Dr. Ben Velazquez, Dr. Manuel A. Moran, Elis Pacheco, Fernando Ferrer, J.I. Starr, John “JellyBean” Benitez, Kenan Thompson, Kim Medina, Little Louie Vega, Luis Guzman, Meiling Macias Toro, Miriam Colon, Nirav Patel, Robert Vazquez, Rafael Toro, Ramon E. Javier, Steve Cox, Tony Ferrara and Vito Bruno
Committee Friends of the Cristian Rivera Foundation:
Carlos Nazario, Edward Caban, Francisco Companioni, Funkmaster Flex, Jerry Chaparro, Mark Rosner, Modesto Lacen, Odalys Molina, Pablo Diaz, Paul Pristavec, Roberto Clemente Jr., Steven Rodas, Teddy “Tedsmooth” Mendez, Victor Martinez, and William Pla
Follow the Cristian Rivera Foundation:
Dr. Mark Souweidane on
Humans of NY
Humans of NY has been doing a 2–week series on pediatric cancer (patients, families, providers) at Memorial Sloan Kettering. Mark Souweidane was interviewed for the series on Tuesday and his segments were posted on Wednesday. It has been an amazing phenomenon for two straight days now – literally hundreds of thousands of comments, likes, shares, and a veritable outpouring of support and love for Mark and his work. You really have to see it to believe it – and it’s truly amazing to read the comments and see the project through the eyes of people hearing about it for the first time.
To Read About it, click the link below
May is Brain Tumor Awareness Month
Join Us As We Fight to End Brain Cancer
Make a Donation @ cristianriverafoundation.org
Every Donation Big or Small Will Bring Us Closer to a Cure!
The Cristian Rivera Foundation is very saddened by the passing of Lauren Hill who succumbed to DIPG this morning, Friday April, 10th 2015. Her courage and drive was an inspiration to all of us. She will never be forgotten.
Today we would like to extend our heartfelt regards to the family of our angel Javier "Buji" Villamil, who earned his wings three years ago today. Help us stop DIPG before another child is lost too soon.
Caitlin Downing Earns Her Wings on Sunday November 11, 2012
Everyone at the Cristian Rivera Foundation would like to express our condolences to the family of Caitlin Downing, who earned her wings on Sunday November 11 surrounded by family and embraced in the loving arms of her parents. Caitlin not only fought bravely in her battle against DIPG but she was a pioneer in the DIPG community as she became the first patient in Dr. Mark Souweidane’s clinical trial in May of this year. Caitlin was a beautiful girl who loved to smile, go to school and put bows in her hair, her mother Denise wrote on her website. Caitlin and Denise were guests of honor at this year’s Fourth Annual Cristian Rivera Foundation Celebrity Gala, where they shared their story about Caitlin’s surgery and subsequent struggle. Caitlin was an inspiration to us all and our thoughts and prayers go out to her entire family.
Olivia Boccuzzi earns her wings on Monday August 20th, 2012
Everyone at the Cristian Rivera Foundation would like to express our condolences to the family of Olivia Boccuzzi, a beautiful girl who earned her wings this past Monday, August 20, 2012 after battling against a brain stem tumor for exactly 11 months. From the moment of her diagnosis, her parents Frank and Enza never gave up hope. They were close friends to The Cristian Rivera Foundation. During their search to help their daughter, they met John Rivera, father of Cristian Rivera and he informed them about Dr. Mark Souweidane & his work associated with children’s brain tumors. Dr. Souweidane met the Boccuzzi’s and he ended up performing a biopsy on the tumor. Olivia had a brain stem tumor but it could not be determined whether it was DIPG or not. This delightful young girl loved dancing like a ballerina, watching Dora the Explorer and playing with her 4-year-old brother James. Olivia was full of energy and love. She is a pioneer in the world of DIPG. Rest in Peace, Olivia. We will never forget your beautiful spirit.
5-year-old Valentina Bravin earns her wings
Everyone at the Cristian Rivera Foundation would like to express our condolences to the family of Valentina Bravin, a beautiful 5-year-old girl who earned her wings this past Thursday, July 12th after battling DIPG for almost 1 year. From the moment of her diagnosis, her parents Eric and Christina never gave up hope, and with the help of Valentina’s grandfather, they started the Friends of Valentina foundation to raise money for medical expenses. Friends of Valentina was able to hold a few fundraisers on Valentina’s behalf last fall, raising thousands of dollars to greatly ease the family’s financial burden. Valentina was a student at St. Luke’s nursery school in Farmingdale, NY, and was an avid lover of ballet, ice skating, and Barbie dolls. Known to the world for being a fighter, Valentina brought hope to lots of people, including John “Gungie” Rivera, the founder of the Cristian Rivera Foundation, who featured Valentina as a Child With Hope at the 3rd Annual Cristian Rivera Foundation Gala last September. Rest in Peace, Valentina. We will never forget your beautiful spirit.
Innovative Clinical Trial Aimed at
Curing Rare Pediatric Brain Tumor Treats First Patient
May 1, 2012—New York, NY—Doctors at Memorial Sloan Kettering Cancer Center and Weill Cornell Medical Center took a major step towards finding a cure for inoperable pediatric brain stem tumor Diffuse Intrinsic Pontine Glioma (DIPG) on Tuesday, May 1, 2012 as work began on the first patient in a pioneering clinical trial spearheaded by Dr. Mark Souweidane. Through the innovative use of convection-enhanced delivery (CED), Dr. Souweidane’s clinical trials will be the first of its kind to administer radio immunotherapy to children with an otherwise incurable tumor.
Denise Pflaumer Downing is the patient’s mother and a Facebook follower of The Cristian Rivera Foundation. She expressed her gratitude for the efforts of the Foundation when she sent this message: “I am sitting at MSKCC in NYC. Right now, my 4 year old daughter is in surgery with Dr Mark Souweidane and his team as they perform the first surgery in a new clinical trial on my daughter. I am so thankful to your foundation for all you have done to support this research and make this trial possible. We must find a cure for DIPG, not only for my child but for all children. Thank you Cristian Rivera Foundation!”
Another sentiment soon followed, this time from Dr. Souwedaine himself.“Today, the first day of Brain Tumor Awareness month, we treated our first patient on our trial using local delivery of a radioimmunotherpeutic agent. The beautiful 4-year-old girl did fantastic and tolerated her surgery like a true champion. Today marks a day of hope for her family, an entry into a new treatment approach for these children, and the culmination of over 12 years of translational research.”
Through this groundbreaking work, Dr. Souweidane and his team aim to ultimately save the lives of approximately 200-300 children who are diagnosed with DIPG each year in the United States. DIPG is typically found in children between the ages of 1 and 9, who are given a bleak prognosis after the tumor is discovered. Median survival is less than one year and the two-year survival rate is less than 20 percent. Currently, there are no recorded survivors and all children diagnosed with the disease typically pass away within 3-18 months.
Helping make these landmark trials possible were donations from top cancer charities with the common goal of making DIPG a thing of the past, including New York City-based not-for-profit 501(c)(3) The Cristian Rivera Foundation, which, to date, has donated approximately $150,000 to Dr. Souweidane’s promising research. John “Gungie” Rivera started the foundation in 2009, months after his 6-year-old son Cristian lost a more than two-year battle with the disease. The Cristian Rivera Foundation is committed to supporting DIPG families and finding a cure for DIPG through education and program funding.
“When my son Cristian was first diagnosed with DIPG, it seemed very unlikely, in fact almost impossible, that a cure would be found in my lifetime,” said Rivera. “Thanks to the amazing courage and interminable spirit of Dr. Souweidane and everyone at the Weill Cornell Pediatric Brain and Spine Center, I firmly believe a cure is within our grasp. Dr. Souweidane gives the DIPG community the hope they so desperately need and I am proud to give him the full support of the Cristian Rivera Foundation as he works toward a cure.”
Mesenchymal Transition and PDGFRA
Amplification/Mutation Are Key Distinct Oncogenic Events
in Pediatric Diffuse Intrinsic Pontine Gliomas
"Two distinct transcriptional subclasses of DIPG with specific genomic
alterations can be defined at diagnosis by oligodendroglial differentiation or
mesenchymal transition, respectively.....Patients in this later group had a
significantly worse outcome with an hazard ratio for early deaths, ie before 10
months, 8 fold greater that the ones in the other. The worse outcome of patients
with the oligodendroglial type of tumors was confirmed on a series of 55
paraffin-embedded biopsy samples at diagnosis (median overall survival of 7.73
versus 12.37 months."
Free Full Text-
Mesenchymal Transition and PDGFRA Amplification/Mutation Are Key Distinct
Oncogenic Events in Pediatric Diffuse Intrinsic Pontine Gliomas.
PLoS One. 2012;7(2):e30313. Epub 2012 Feb 28.Puget S, Philippe C, Bax DA, Job B,
Varlet P, Junier MP, Andreiuolo F, Carvalho D, Reis R, Guerrini-Rousseau L,
Roujeau T, Dessen P, Richon C, Lazar V, Le Teuff G, Sainte-Rose C, Geoerger B,
Vassal G, Jones C, Grill J.
Department of Neurosurgery, Necker-Sick Children Hospital, University Paris V
Descartes, Paris, France.
Diffuse intrinsic pontine glioma (DIPG) is one of the most frequent malignant
pediatric brain tumor and its prognosis is universaly fatal. No significant
improvement has been made in last thirty years over the standard treatment with
radiotherapy. To address the paucity of understanding of DIPGs, we have carried
out integrated molecular profiling of a large series of samples obtained with
stereotactic biopsy at diagnosis. While chromosomal imbalances did not
distinguish DIPG and supratentorial tumors on CGHarrays, gene expression
profiling revealed clear differences between them, with brainstem gliomas
resembling midline/thalamic tumours, indicating a closely-related origin. Two
distinct subgroups of DIPG were identified. The first subgroup displayed
mesenchymal and pro-angiogenic characteristics, with stem cell markers
enrichment consistent with the possibility to grow tumor stem cells from these
biopsies. The other subgroup displayed oligodendroglial features, and appeared
largely driven by PDGFRA, in particular through amplification and/or novel
missense mutations in the extracellular domain. Patients in this later group had
a significantly worse outcome with an hazard ratio for early deaths, ie before
10 months, 8 fold greater that the ones in the other subgroup
(p = 0.041, Cox regression model). The worse outcome of patients
with the oligodendroglial type of tumors was confirmed on a series of 55
paraffin-embedded biopsy samples at diagnosis (median OS of 7.73 versus 12.37
months, p = 0.045, log-rank test). Two distinct transcriptional
subclasses of DIPG with specific genomic alterations can be defined at diagnosis
by oligodendroglial differentiation or mesenchymal transition, respectively.
Classifying these tumors by signal transduction pathway activation and by
mutation in pathway member genes may be particularily valuable for the
development of targeted therapies.
Fairfield woman cuts hair to raise awareness
for disease, honor fallen son
March 9, 2012
Randy Hill a barber at J's Barber Shop in Suisun City shaves the words "Cure" and "DIPG" into the hair of Danah Jewett of Fairfield on Thursday. Her son, Dylan, died of the rare brain tumor in January of 2009, less than two-months after he was diagnosed. (Joel Rosenbaum/JRosenbaum@TheReporter.com)
BY KIMBERLY K. FU/ KFU@THEREPORTER.COM
Weary of grieving, a young Fairfield mom who lost a son to brain stem cancer three years ago took a bold step Thursday in her journey toward healing -- she shaved her head.
And embedded two important words on the newly buzzed canvas -- CURE DIPG.
"As fun as all this is, it's really about the kids. Remembering Dylan and honoring the kids," emphasized Danah Jewett, 34, as she fingered her spiky new do compliments of Randy Hill at J's Barber Shop off Sunset Avenue in Suisun City. Touched by her cause, Hill donated his services.
Jewett's son, 5-year-old Dylan, died of the rare and inoperable Diffuse Intrinsic Pontine Glioma (DIPG) in 2009 just two months after his diagnosis.
Randy Hill a barber at J's Barber Shop in Suisun City shaves the words "Cure" and "DIPG" into the hair of Danah Jewett of Fairfield on Thursday. Her son, Dylan, died of the rare brain tumor in January of 2009, less than two-months after he was diagnosed. (Joel Rosenbaum/JRosenbaum@TheReporter.com)
Not much is known about the condition, so the family donated Dylan's brain tumor to Stanford University School of Medicine for further research. His cells were the first living specimen of DIPG in the world and resulted in significant discoveries, including the cell of origin. By understanding which cell causes the tumor, Jewett said, scientists can further understand the disease.
Dylan's mom hopes to bring more awareness of the disease, as well as of the courageousness of all children who are living with cancer.
"My job, as Dylan's mother, is to make sure his memory lives on, raise awareness about this deadly cancer and tell others about DIPG, and hope that funding will somehow become available," she said. "Children are dying and there is a way to make it stop."
Still coming to terms with her own loss, Jewett sponsored the inaugural "Dylan's Warriors Prayer Walk" in Vacaville's Lagoon Valley Park last September. A sequel is planned for this September, complete with run/walk T-shirts and giveaways of gold and gray ribbons representing childhood cancer and brain cancer. Details will be revealed by June or July.
In recent months, Jewett's heart has remained heavy. Her family, which includes husband John, who is stationed at Travis Air Force Base, and a son, 4-year-old Jayden, encouraged her to do more for herself. So she did, literally using her head as a tool.
Visiting her hairstylist at "Twisted" in Fairfield, Jewett had her long brown locks separated into 56 braids. Friends and family donated $10 or more per braid for cancer research and, beginning on the anniversary of Dylan's death, she began cutting one braid each day. Meanwhile, she also communed with her faith, delved deep into herself and prayed for renewal.
Randy Hill a barber at J's Barber Shop in Suisun City shaves the words "Cure" and "DIPG" into the hair of Danah Jewett of Fairfield on Thursday. Her son, Dylan, died of the rare brain tumor in January of 2009, less than two-months after he was diagnosed. (Joel Rosenbaum/JRosenbaum@TheReporter.com)
"I wanted to seek an intimate relationship with God, just think of God and Dylan, what Dylan meant to me," she explained. "I wanted a process for it, I wanted more than to shave it off and it's over."
By having "CURE DIPG" nearly carved into her head, Jewett said there's no way that she won't generate notice for the condition. Her braids had already caused a mild sensation -- the new hairdo is likely to generate an explosion.
"This year is about Dylan, remembering him, honoring him, about DIPG and what it stole from us," she said. "I want people to think about things, about kids with cancer. It's just so amazing, what they go through."
Even children have asked about DIPG, Jewett said, recalling a 9-year-old girl at church who was so inspired by Jewett's hair that she gave her a $5 donation and pledged to do more to help.
Thus far, Jewett has raised about $400 for Lucile Packard Children's Hospital for DIPG research and plans to donate her hair to Locks of Love, an organization that makes wigs for cancer patients.
For more information, go online to www.curedipg5.com
Race funds cancer research
March 8, 2012
By Anne Cloonan
The Fifth Annual Race For Grace will be held March 31 at Norwin High School. The race, which includes a five-kilometer run, five-kilometer walk and a one-mile walk, will benefit the Reflections Of Grace Foundation.
The race and the foundation it benefits are named for Grace Elizabeth Ekis, a 5-year-old who died on Valentine's Day 2008 after a 13-month battle with a rare brain tumor, according to the foundation's website, run by Brian and Tamara Ekis, Grace's parents.
The foundation provides financial, educational and emotional support to the families of children with brain cancer.
Grace's cancer was a diffuse intrinsic pontine glioma, or a tumor of the brainstem that has no known cure and for which no advances in treatment options have been made for more than 30 years, according to the website.
The website describes it as one of the worst forms of childhood brain cancer. Approximately 150 to 200 children are diagnosed with this type of tumor each year, and survival time is typically nine to 12 months.
In 2011, the race had 1,800 registered runners and walkers, 300 volunteers and 300 spectators, and raised more than $88,000 for the families of children with brain cancer.
That was an increase in funds raised from 2010, when 2,000 attended and more than $70,000 was raised for the families of children with brain cancer.
Opening activities for the 2012 race will begin at 7 a.m. March 31, and the race itself will start at 9 a.m. at the high school at 251 McMahon Drive, North Huntingdon.
Registration fees will be $25 for adults and $20 for children age 12 and younger. A waiver must be signed for each participant, regardless of age.
The Reflections Of Grace Foundation is a nonprofit organization; www.reflectionsofgrace.org
Coins For The Cure: Village Elementary School Raises Funds
For Pediatric Brain Cancer Research
March 8, 2012
Coins For The Cure: Village Elementary School Raises Funds For Pediatric Brain Cancer Research
Coronado's Village Elementary School Student Council representatives presented a check for $379 to the McKenna Claire Foundation, a foundation dedicated to finding the cause and the cure for Pediatric Brain Cancer. The fund drive was part of the student council's year-long project to raise money and awareness for underfunded issues that impact children.
Each month, the Village Elementary Student Council selects a different cause to support. January's cause was pediatric brain cancer. Previous months focused on juvenile diabetes and pulmonary hypertension. March will be dedicated to raising money for the Coronado Schools Foundation. For every cause, the student council decorates and distributes classroom "coin" jars, collects and counts the money, posts signs around campus and encourages students to learn more about these very important issues.
Student council advisors, Ms. Shady, Ms. Garner, and Mr. Elderson, encourage students to build community and support philanthropic efforts. All three teachers emphasize that this project has been completely student driven, making it even more special. Fifth graders, Jack Outlaw and George Farley, raised the idea of supporting the McKenna Claire Foundation. Both said they heard McKenna's story and wanted to help other children.
McKenna, a vivacious, seemingly healthy, 7-year-old from Huntington Beach was suddenly diagnosed with a rare, inoperable brain stem tumor called Diffuse Intrinsic Pontine Glioma (DIPG). DIPG tumors, like many pediatric brain tumors, have very low survival rates. In July 2011, McKenna Claire lost her battle with cancer just six months after diagnosis.
The McKenna Claire Foundation's mission is to cure pediatric brain cancer by raising awareness, increasing community involvement and funding research. One of the foundation's near-term objectives is to raise money for innovative research being conducted at Stanford University's Monje Lab. Using cell cultures from children who have donated their tumors to research, including McKenna Claire, the Monje Lab is dedicated to understanding how DIPG tumors originate, the molecular signals that drive their growth, and novel ways to treat DIPG.
To learn more or donate visit: mckennaclairefoundation.org
. For more information about the Monje Lab please visit: http://neurology.stanford.edu/labs/monjelab
Charlotte Christian freshman crowned Miss Mecklenburg
February 3, 2012
Charlotte Christian-Payton Walker-Miss Mecklenburg. Photo courtesy of Charlotte Christian.
By Lauren Bailey
Charlotte Christian freshman Payton Walker was named the 2012 Miss Mecklenburg Outstanding Teen Jan. 21. The program is part of the Miss America scholarship pageant.
Payton will spend the next year participating in community service in the area and will represent Mecklenburg County in the Miss North Carolina Outstanding Teen Pageant, to be held in June in Raleigh.
Payton's platform will include raising awareness about diffuse intrinsic pontine glioma, a rare pediatric brain cancer. Payton is at the top of her class at Charlotte Christian, where she serves as a student ambassador and student government president.
Showing 'Love for Lexi'
February 3, 2012 – 4:54 pm
By Stacey Tucker - Staff Writer
CASS CITY — The Cass City community and surrounding area are gathering Saturday (today) to show their 'Love for Lexi."
A benefit dinner and auction is planned, beginning at 2 p.m. at the Cass City High School to benefit the family of Lexi Smith, a six-year-old diagnosed with an inoperable brain tumor.
"We're just very grateful and very appreciative for what everyone has done," said Heidi Smith, Lexi's mother. "We've just been overwhelmed with gratefulness."
Heidi and her husband Randy have stepped away from their jobs, Heidi's in the office at Erla's Foods and Randy's at Axly Production Machining in Bad Axe so the pair can spend more time with their daughter.
"We decided to stay home and spend as much time with her as possible," she said. "We have a lifetime of memories to make in a short amount of time."
Lexi was diagnosed with Diffuse Intrinsic Pontine Giloma (DIPG) in early December 2011. DIPG is a tumor located in the middle of the brain stem that connects the cerebrum with the spinal cord.
The tumor is extremely rare, affecting only 150 to 200 children each year.
According to Reflections of Grace, a foundation supporting families of children diagnosed with DIPG, over 90 percent of children diagnosed with the tumor aren't expected to live longer than 18 months.
Heidi Smith said her daughter initially came to her one morning, unable to put three fingers up together. Concerned, they took Lexi to the hospital, where a cat scan came back clear.
Heidi said she still had a bad feeling about it, and they took her to a hospital in Saginaw where she talked with their pediatric neurologist.
"We had an MRI scheduled for the following Wednesday, but by Thursday her symptoms had worsened and we went back in for an emergency MRI," Smith said.
That is when doctors were able to diagnose Lexi's condition and she was sent to U of M Mott Children's Hospital to begin radiation.
After six weeks of aggressive radiation, Lexi is now home with her family and her symptoms have decreased.
"She had weakness on her left side, it was difficult for her to walk and she had difficulty seeing on her left side," Smith said. "All these symptoms have decreased, she's able to walk and her sight is back."
Unfortunately, Smith said this type of tumor is very aggressive and could come back even worse within months.
"When it comes back it comes back hard and very aggressive," she said. "In her case they think it will recur in three months."
Smith said that is why it is so important for them to spend as much time now as they can with their daughter.
To help the family with costs, the spaghetti dinner benefit will be a $7 donation per adult and $3 per child 12 years of age and under.
The benefit will include live music and there will be a silent auction from 2-6 p.m. A live auction will begin at 6 p.m. while the movies "Dolphin Tale" and, if time permits, The Smurfs will be played for kids. Popcorn and juice will be offered during the movie.
"There's quite a bit going on," said Shari Bock, coordinator of the event. "Lexi is a Girl Scout member, so the Girl Scouts will be having a bake sale.
"We're going to have arts and crafts set up so the kids can make Valentine's Day cards for Lexi."
The Cass City Schools superintendent Jeff Hartel will be selling 50/50 tickets with a drawing at 5:45 p.m., and Johnny Burke from 96.1 WHNN donated a flat screen TV that will be raffled off.
The event is sponsored by Thrivent Financial for Lutherans, Women's Life Chapters 848 and 877, Cass City Lions Club, Cass City Public Schools and Erla's Foods.
This Testimony is Embargoed Until Thursday, February 2nd at 9:00 AM
Please visit: http://waysandmeans.house.gov/committeesubmissions/ and submit your comment for the record. There are many of us out there
who have suffered as the result of losing our child and then having a
thief take our kids' social security numbers. Please consider submitting
FROM: Jonathan Eric Agin, Esq.
TO: House Ways and Means Committee,
Subcommittee on Social Security
DATE: February 2, 2012
RE: H.R. 3475
Good morning Mr. Chairman and members of the Committee. Thank you for allowing
me to be here today to testify on this issue of vital importance.
My family's story begins with the diagnosis of our amazing daughter, Alexis Gina Agin,
with a terminal brain tumor at the age of two on April 10, 2008. Ultimately, this terrible disease
took her life on January 14, 2011, just two weeks shy of her fifth birthday. Alexis was and is my
hero. Fighting valiantly until the end, she has inspired thousands around the world with her
In 2010, my wife and I travelled with Alexis up and down the East Coast trying several
experimental treatments, in a desperate attempt to save her. With each trip, Alexis' medical bills
mounted. When it came time to file our 2010 taxes, compiling all of our receipts for the medical
expenses was time-consuming and emotionally draining. Accordingly, my wife and I, through
our accountant, filed with the IRS for an extension. In October 2011, after completing the
difficult and grueling task of finalizing our 2010 taxes, I received a telephone call from our
accountant advising us that someone had already filed a tax return for 2010 using Alexis' social
security number. Beyond being completely stunned at that very moment, we were advised that
we would not be able to file an electronic return. Instead, our accountant would have to
complete the paper forms and file them in the traditional manner. More importantly for purposes
of HR 3475, he told us that we ultimately would have to prove that our deceased daughter was,
in fact, our daughter. In situations involving this type of criminal fraud, the IRS credits the first
filer and presumes that the initial filing is accurate.
That same day, we reached out to the community of grieving cancer parents that we have
come to know since April 2008 and told them what had happened. With incredulous
amazement, we learned within a single hour of no fewer than fourteen other families whose
children had died and also had experienced the additional travesty of their child's social security
number being stolen. Clearly we were not alone. We then learned through our own research and
from other parents that this is, in fact, a very widespread issue impacting parents who lose a child
due to any and all reasons imaginable.
Not surprisingly, when I first learned that Alexis' social security number had been
fraudulently used, I wanted to know how someone could have found it. Within a matter of
seconds on the internet, I was able to locate her complete social security number and other
personal identifying information, including her birth and death dates, on several websites
intended for genealogical research. I immediately contacted one of the services, who directed
This Testimony is Embargoed Until Thursday, February 2nd at 9:00 AMme to the service's outside counsel. When I asked the attorney to remove my daughter's
personal information from the website, he advised me that the service was within its legal rights
to display the information and that it refused to remove her social security number. The attorney
cited as support for their position a 1980 consent judgment between the United States
Government and a private citizen, Ronald Perholtz. It was at that point that we truly realized
how significant this problem is, and more importantly, how the federal government is partly to
blame. It is my belief that the federal government is responsible for providing identity thieves
the information required to commit this costly crime. By affording widespread access to this
type of information, the federal government provides the perfect platform for the commission of
The common denominator in this story is the Death Master File (hereinafter "DMF").
The Social Security Administration makes the DMF available to the National Technical
Information Service (NTIS) of the Department of Commerce, who then sells the DMF to private
and public sector customers, including government agencies, financial institutions, investigative
entities, credit reporting organizations, genealogical researchers and other industries. Some of
these purchasers, namely organizations hosting websites aimed at facilitating genealogical
research, then make available the DMF for free to the public at large. It therefore is available to
nearly anyone and perpetuates identity theft and fraud against the federal and state governments
at astronomical levels. As a taxpayer and parent of a child who passed away from cancer, I am
outraged at the most private information of our children being made commercially available.
Not only is this a significant invasion of my child's privacy, but it adds to the tremendous grief
that my wife and I live with on a daily basis and will continue to live with for the rest of our
lives. While it may seem trivial to some, Alexis' social security number is one of the only things
that we have left of her identity. Thus, the theft of it robbed us of something truly priceless.
Due to an ongoing media probe and public pressure, the IRS for the first time recently
responded to inquiries on this issue, and estimated that there were approximately 350,000
fraudulent tax filings in 2010. According to IRS officials, these fraudulent filings claimed $1.25
billion in refunds.1
The cost to the federal government to investigate and prosecute that
magnitude of fraud could be spent in much better ways, including research to fund cures for our
In addition, it is worth noting that the federal government discloses far more information
than is required under the 1980 settlement. In June 2008, the Inspector General of the Social
Security Administration issued a critical report detailing how publication of the DMF has
resulted in the breach of citizens' personally identifiable information.2
The report concludes that
the Social Security Administration "discloses far more detailed personal information in the DMF
than required under the original consent judgment that resulted in the creation of the DMF.
Under the terms of the agreement, SSA was to compile a list that identified deceased
numberholders' SSNs, surnames and dates of death. However, SSA expanded the information
published in the DMF to include the decedent's date of birth, first and middle name, and last
known residential state/zip code."3
The report's conclusion is simple: less information should be
released, and greater efforts at accuracy and protection must be taken.
Significantly, Ronald Perholtz, the man who filed the lawsuit that led to the 1980 consent
judgment resulting in creation of the DMF, sought release of the information to help reduce
fraud. Specifically, he wanted the information as a tool for pension companies to identify theft
of pension benefits. Soon after learning the DMF was created, Mr. Perholtz learned that the
DMF frequently listed the social security numbers of people who were not, in fact, dead.4
Now, he believes that changes need to be made in order to stop this type of fraud. Indeed, Mr. Perholtz
stated that he is willing to renegotiate the original settlement as he feels so strongly that the DMF
is being abused.5
H.R. 3475 is a solution to a significant problem that affects not only grieving parents, but
also every family who loses a loved one. It also is a solution to a problem that was never
anticipated, and would eliminate dissemination by the federal government of extraneous
information that it is not required to release. This additional information, along with the readily
accessible nature of individuals' social security numbers, has provided identity thieves an avenue
to commit this crime and defraud the taxpayers and government.
Those who argue that the release of this information is critical to combat fraud and
conduct genealogical research fail to understand that this Bill is not intended to prevent or limit
the lawful use of Social Security Numbers or genealogical research. First, I would say to any
individual conducting genealogical research, why do you need to know my daughter's social
security number? Why should it be publicly available to anyone with a computer? What
purpose does her full social security number, along with her birth and death dates, address, and
other personal identifying information have for your familial research? The clear answer is that
it has absolutely no purpose. Alexis didn't die a long time ago—she died last year. While it may
be difficult to find information about your ancestors from generations ago, it should not be hard
to confirm your familial connection (or lack thereof) to someone born just six years ago.
More importantly, this Bill will not prevent credit bureaus and financial institutions from
fulfilling their charge of protecting us from fraud. To the contrary, because access to this
information will be more restricted, these institutions will be more empowered knowing that the
potential incidence rates of identity theft and fraud will be curtailed. Potentially far fewer
instances of fraud against lawful citizens will be committed, thus reducing the amount of
investigation necessary. The intent of this legislation is not to limit or prohibit financial
institutions from investigating fraud; rather it is to prohibit the widespread publication and easy
access of personal information that is utilized by criminals to defraud the government. As for
hospitals and other institutions who claim to utilize the DMF to determine if their patients are
deceased, I submit that there are other far less destructive methods to make such determinations
and conduct your research. Again, this Bill is not aimed at those who have a legitimate need for
access to individuals' social security numbers and they will continue to have access to this
I have been told that in most cases, the government does not have the resources to
prosecute this crime. It either is too costly, or the government simply does not have the ability to
track and punish those who are stealing from it and taxpayers alike. If this crime was prevented,
to the best extent possible upfront with this simple measure, there would be little concern
regarding the cost to prosecute as more resources could be made available, stiffer penalties
proscribed and additional deterrents fully understood.
In closing, this is not a victimless crime. My daughter is a victim. She was victimized
twice. Once by the cancer that stole her from this earth, and then by a cold-hearted criminal who
stalked her and utilized her death for profit. It disgusts me to no end to know that someone
prayed upon my daughter's death for his or her own gain. It is an added insult for a grieving
parent. It is nothing short of a despicable crime and the release of Alexis' complete social
security number and other personal identifiers to the general public facilitated this crime. But
this simply is not an emotionally charged issue, as some argue. Fraud is not something that we
simply should accept as a necessary consequence of easy access to information. Yes, security
breaches will always be possible regardless of the measures that we put into place. But when
there is a simple fix to a significant problem that affects all taxpayers, the fix should be taken
seriously and enacted with haste. It is time that this loophole is closed and this legislation is the
manner in which to accomplish this aim. Nothing short of this will accomplish the task. It is
simple and to the point, and in this era when our government is struggling to find ways to save
money for the taxpayer, it is a very easy fix with little to no consequences or repercussions to
citizens of this country.
Thank you Mr. Chairman and distinguished members of the Committee.
Jonathan Eric Agin
1 Dale McFeatters, Govt. shares blame as ID theft worsens, available at
(November 5, 2011).
2 Office of the Inspector General, Social Security Administration, Personally Identifiable Information Made
Available to the General Public Via the Death master File, Audit Report A-06-08-18042 (June 2008).
3 Id. at 6.
4 Thomas Hargrove, Social Security 'Death File' designed to fight fraud but now aids it, available at
www.scrippsnews.com (November 14, 2011).
Cancer sequencing initiative discovers mutations tied to
aggressive childhood brain tumors
Memphis, Tennessee, January 29, 2012
St. Jude Children's Research Hospital – Washington University Pediatric Cancer Genome Project provides first evidence linking cancer to mutations in genes involved in DNA organization
Researchers studying a rare, lethal childhood tumor of the brainstem discovered that nearly 80 percent of the tumors have mutations in genes not previously tied to cancer. Early evidence suggests the alterations play a unique role in other aggressive pediatric brain tumors as well.
The findings from the St. Jude Children’s Research Hospital – Washington University Pediatric Cancer Genome Project (PCGP) offer important insight into a poorly understood tumor that kills more than 90 percent of patients within two years. The tumor, diffuse intrinsic pontine glioma (DIPG), is found almost exclusively in children and accounts for 10 to 15 percent of pediatric tumors of the brain and central nervous system.
“We are hopeful that identifying these mutations will lead us to new selective therapeutic targets, which are particularly important since this tumor cannot be treated surgically and still lacks effective therapies,” said Suzanne Baker, Ph.D., co-leader of the St. Jude Neurobiology and Brain Tumor Program and a member of the St. Jude Department of Developmental Neurobiology. She is a corresponding author of the study published in the January 29 online edition of the scientific journalNature Genetics.
DIPG is an extremely invasive tumor that occurs in the brainstem, which is at the base of the skull and controls such vital functions as breathing and heart rate. DIPG cannot be cured by surgery and is accurately diagnosed by non-invasive imaging. As a result, DIPG is rarely biopsied in the U.S. and little is known about it.
Cancer occurs when normal gene activity is disrupted, allowing for the unchecked cell growth and spread that makes cancer so lethal. In this study, investigators found 78 percent of the DIPG tumors had alterations in one of two genes that carry instructions for making proteins that play similar roles in packaging DNA inside cells. Both belong to the histone H3 family of proteins. DNA must be wrapped around histones so that it is compact enough to fit into the nucleus. The packaging of DNA by histones influences which genes are switched on or off, as well as the repair of mutations in DNA and the stability of DNA. Disruption of any of these processes can contribute to cancer.
Researchers said that the mutations seem unique to aggressive childhood brain tumors.
“It is amazing to see that this particular tumor type appears to be characterized by a molecular ‘smoking gun’ and that these mutations are unique to fast-growing pediatric cancers in the brain,” said Richard K. Wilson, Ph.D., director of The Genome Institute at Washington University School of Medicine in St. Louis and one of the study’s corresponding authors. “This is exactly the type of result one hopes to find when studying the genomes of cancer patients.”
The results are the latest from the PCGP, an ambitious three-year effort to sequence the complete normal and cancer genomes of 600 children with some of the most poorly understood and aggressive pediatric cancers. The human genome includes the complete set of instructions needed to assemble and sustain human life. The goal is to identify differences that explain why cancer develops, spreads and kills. Researchers believe the findings will provide the foundation for new tools to diagnose, treat or prevent the disease.
For this study, researchers sequenced the complete normal and cancer genomes of seven patients with DIPG. “The mutations were found at such high frequency in the cancer genomes of those seven patients that we immediately checked for the same alterations in a larger group of DIPGs,” Baker said. When researchers sequenced all 16 of the related genes that make closely related variants of histone H3 proteins in an additional 43 DIPGs, they found many of the tumors contained the same mistakes in only two of these genes.
Of the 50 DIPG tumors included in this study, 60 percent had a single alteration in the makeup of theH3F3A gene. When the mutated gene was translated into a protein, the point mutation led to the substitution of methionine for lysine as the 27th amino acid in this variant of histone H3 protein. Another 18 percent of the DIPG patients carried the same mistake in a different gene, HIST1H3B.
Researchers are now working to understand how mutations in H3F3A and HIST1H3B impact cell function and contribute to cancer. Earlier research provides some clues. The lysine that is mutated is normally targeted by enzymes that attach other molecules to histone H3, influencing how it interacts with other proteins that regulate gene expression, Baker said. Mutations in the enzymes that target histone H3 have been identified in other cancers, but this is the first report showing a specific alteration of histones in cancer.
H3F3A and HIST1H3B were also mutated in other aggressive childhood brain tumors, glioblastoma, that develop outside the brain stem. Of 36 such tumors included in this study, 36 percent carried one of three distinct point mutations in the genes. The alterations included another single change in the makeup of H3F3A not found in DIPGs.
The histone H3 genes, however, were not mutated in any of the 252 other childhood tumors researchers checked for this study. The list included the brain tumors known as low-grade gliomas, medulloblastomas and ependymomas plus other cancers outside the brain and nervous system. The H3 changes have not been reported in any other cancers, including adult glioblastoma. “This suggests these particular mutations give a very important selective advantage, particularly in the developing brainstem and to a lesser degree in the developing brain, which leads to a terribly aggressive brain tumor in children, but not in adults,” Baker said.
“This discovery would not have been possible without the unbiased approach taken by the Pediatric Cancer Genome Project,” Baker said. “The mutations had not been reported in any other tumor, so we would not have searched for them in DIPGs. Yet the alterations clearly play an important role in generating this particular tumor.”
The study’s first authors are Gang Wu, Alberto Broniscer and Troy McEachron, all of St. Jude. The study’s other corresponding authors are Jinghui Zhang and James Downing, both of St. Jude. The other study authors are Charles Lu, Li Ding and Elaine Mardis, all of Washington University; and Barbara Paugh, Jared Becksfort, Chunxu Qu, Robert Huether, Matthew Parker, Junyuan Zhang, Amar Gajjar, Michael Dyer, Charles Mullighan, Richard Gilbertson and David Ellison, all of St. Jude.
The research was funded in part by the PCGP, including Kay Jewelers, a lead project sponsor; the National Institutes of Health, the Sydney Schlobohm Chair of Research from the National Brain Tumor Society; the Cure Starts Now Foundation, Smile for Sophie Forever Foundation, Tyler’s Treehouse Foundation, Musicians Against Childhood Cancer, the Noyes Brain Tumor Foundation and ALSAC.
St. Jude Children’s Research Hospital
Since opening 50 years ago, St. Jude Children’s Research Hospital has changed the way the world treats childhood cancer and other life-threatening diseases. No family ever pays St. Jude for the care their child receives and, for every child treated here, thousands more have been saved worldwide through St. Jude discoveries. The hospital has played a pivotal role in pushing U.S. pediatric cancer survival rates from 20 to 80 percent overall, and is the first and only National Cancer Institute-designated Comprehensive Cancer Center devoted to children. It is also a leader in the research and treatment of blood disorders and infectious diseases in children. St. Jude was founded by the late entertainer Danny Thomas, who believed that no child should die in the dawn of life. Join that mission by visiting www.stjude.org or following us on www.facebook.com/stjude and Twitter@StJudeResearch.
Washington University School of Medicine
Washington University School of Medicine’s 2,100 employed and volunteer faculty physicians also are the medical staff of Barnes-Jewish and St. Louis Children’s hospitals. The School of Medicine is one of the leading medical research, teaching and patient care institutions in the nation, currently ranked fourth in the nation by U.S. News & World Report. Through its affiliations with Barnes-Jewish and St. Louis Children’s hospitals, the School of Medicine is linked to BJC HealthCare.
St. Jude Media Relations Contacts
Washington University Media Relations Contact
(cell) (314) 445-4172
(desk) (314) 286-0109
A soo-weet collaboration between
entrepreneurship, philanthropy, and BBQ
By Adriana Lopez
This post is dedicated to the memory of Ben Sarrat Jr. for the movement he inspired.
Hogs for the Cause founders Becker Hall and Rene Louapre
with their inspiration, Ben.
The formula for the first annual pig roast was simple: a few friends, a pig, and a keg. However, when Hogs for the Cause
founders Becker Hall and Rene Louapre met Ben Sarrat, Jr., they were inspired to use their pig roast at the Fly to raise money for a family friend in need.
With that newfound motivation and drive, the duo has turned what was an idea for a small, pork infused gathering with friends into a highly anticipated festival that continues to triple in size each year.
In true New Orleans form, Hall and Louapre go back to childhood. Having grown up together, they always considered each other as brothers, and now play the roles of business partners with equal ease. Part of their success can be traced to the evident camaraderie and balance between the businessman and the lawyer, but their conviction and motivation has turned the young professionals into moonlighting entrepreneurs and philanthropists.
In 2009, the two friends and culinary aficionados came up with the idea of hosting a pig-roast, a tailgate tradition from Hall's alma mater at the University of South Carolina, and a surprisingly new concept to New Orleans.
Shortly after they decided to add a philanthropic component to their roast, they met Ben. The young son of a family friend had been diagnosed with DIPG, an incurable brain tumor that cannot be removed because of its location on the brain stem, typically giving those who are diagnosed only one year of survival after detection. Hall and Louapre were taken by Ben's enthusiasm and courage and decided to use their pig roast to raise money to help him and his family. Within a month, Hogs for the Cause was incorporated and registered as a 501c(3) non-profit organization.
"Meeting Ben was a really profound moment for us both, and immediately changed everything," Hall says of this pivotal moment that inspired their endeavor. "Even with such terrible circumstances, he still continued to have a genuine enthusiasm for life. At that point, we decided to do whatever we could to help Ben have the happy childhood he deserved."
In their first year, Hall and Louapre, along with 250 friends, raised $10,000 to help support Ben's family with their expenses. However, they knew they could do more.
The week before their second Hogs for the Cause, Ben tragically lost his battle to DIPG. However, his story only reinforced Hall and Louapre's mission and drive to continue their fundraising for other families. In its second year, Hogs for the Cause drew in 2,500 people and raised $30,000, with a large portion of it going to support families like the Sarrats.
Hogs for the Cause's mission is to alleviate some of the financial burden families face when a child is being treated for pediatric brain cancer. The money raised goes toward grants that help cover the peripheral expenses that insurance does not otherwise pay for, such as travel and lodging expenses incurred during cancer treatment.
Hall and Louapre filled a void of funding resources for pediatric cancer outreach services, as well as another void that New Orleans was ironically missing: pork cook-offs. In 2011, Hogs for the Cause moved from the Fly to City "Pork," where they raised $100,000 for their cause, along with the help of 45 teams battling it out with their pork creations and 7,000 attendees.
And that was only year three.
This year, within three weeks of registration opening, 60 spots were filled with teams of pork enthusiasts, amateur cooks, award-winning BBQ experts, and renowned chefs and restaurant owners. Besides their genuine enthusiasm to support the cause, the teams participate for the opportunity to prove their culinary skills and compete for the ultimate title of Grand Champion. To them, the pork cook-off is merely the grand finale of a year spent practicing recipes and practicing witty twitter banter and intimidation between the teams. (I train my stomach's pork capacity by reading their twitter feeds during this time. I recommend you do the same.)
The participants all compete in several categories, including Ribs, Whole Hog, Butt, Porkpourri, Grand Champion (who must Compete in three of the four aforementioned categories), Best Booth and Presentation, Fundraising Champion, Best Sauce, and Fan Favorite, which gives the fans a voice and opportunity to vote through the Hogs for the Cause iPhone app
While Hogs for the Cause founders are grateful for the loyalty and enthusiasm of all the competitors, the team members continue to gain recognition for their participation in the competition as well. After winning last year's Porkpourri category, Chef Adam Biderman credited his participation in Hogs for the Cause for the inadvertent loyal following he built before opening The Company Burger last August.
This year, Biderman will be back to defend his title and continue his support to the cause, along with other local chefs, including Aaron Burgau of Patois, Drew Dzejak of The Windsor Court's Grill Room, Chefs Allison and Slade Rushing from MiLa, and Le Petite Grocery's Chef Justin Devillier, just to name a few.
Hogs for the Cause is March, 24th 2012
Hogs for the Cause is March, 24th 2012
Six bands have also been confirmed to perform on the NOLA Brewing
stage this year, including Trombone Shorty & Orleans Avenue
, Voice of the Wetlands All-Stars
, 2012 Grammy nominated artist Marcia Ball
, The Stooges Brass Band, Mississippi Rail Company
, and Austin, Texas' The Gourds
While the event now launches the beginning of festival season in New Orleans and continues to grow significantly each year, Hall and Louapre still find that the greatest reward is being able to help their grant recipients.
"The greatest feeling in the world is walking into a room and delivering to a family a sign of hope," said Louapre about his motivation to continue the growth of the annual cook-off. "These are families with odds stacked against them. Their child is fighting against a brutal killer, and to be able to deliver just a small dose of help -- a reassurance that people care and a big hug of humanity -- makes it all worth it."
The entrepreneurial-minded team attributes the growth of their brand to their conviction and passion to help the families in need. And, when asked about where they see Hogs for the Cause in five years, they both agreed on being at the forefront of funding sources for pediatric brain cancer outreach services.
Louapre added, "The cook-off will have 125 teams, there will be two stages of live music, and Becker and I (who have known each other our whole lives and are almost brothers) will still be fighting over minor details as we continue to make Hogs better."
Hall's vision includes taking the fundraising to a national level with cook-offs across the country.
While they might already be sparring about the exact coordinates of their five-year benchmark, it's unmistakable that their brotherly dynamic has helped them surpass even their own expectations. So, who's to say it won't all be possible?
The country's largest cook-off and nationally renowned charity based out of New Orleans is merely just a baby step toward what they can accomplish together.
What's in store for March 24, 2012? Meatier competition, a new music lineup, larger location in City "Pork," an adult "porkade," frolf (frisbee-golf) games, a new iPhone app, and bigger fundraising goals.
To learn more, purchase tickets, and make a donation
, visit their website
, and follow them on Twitter
for all the updates and witty pork puns. Download the iPhone app
to learn more about Hogs for the Cause, stay updated with the competition, vote for fan favorite, and purchase tickets.
Pre-Sale General admission tickets for $10, as well as ticket packages that include unlimited food and beer, judging privileges, and access to the "Boss Hog" tent, are available now and can be purchased online
or on the iPhone App
PATIENT GROUPS AND RESEARCHERS JOIN FORCES TO SPEED TREATMENTS FOR RARE PEDIATRIC BRAIN TUMOR
Four Organizations Fund International Research Consortium to Improve Lives of Children Suffering From Diffuse Intrinsic Pontine Glioma (DIPG)
Accelerate Brain Cancer Cure (ABC2
), CureSearch for Children's Cancer, The Cure Starts Now Foundation and The Lyla Nsouli Foundation for Children's Brain Cancer Research today announced their collaborative funding to support groundbreaking research aimed at dramatically improving the lives of children suffering from Diffuse Intrinsic Pontine Glioma (DIPG) – one of the most devastating pediatric cancers.
Together, the four organizations have committed $229,000 to support the work of the DIPG Preclinical Consortium, the only international scientific group focused on preclinical development of targeted therapy combinations for DIPG. The goal of the research is to test and then move the most effective therapy forward to early phase clinical trials in the next 18 – 24 months.
Children with DIPG have a uniformly dismal prognosis with a median survival of 9 months. A DIPG tumor grows amidst the nerves in the pons (middle) of the brain stem, and therefore cannot be surgically removed. Radiotherapy provides only temporary improvement of symptoms. No chemotherapy has ever proven effective. Novel therapies are desperately needed. "The scientific community has truly rallied around this cause. The mandate for a novel therapeutic approach was born in the Children's Oncology Group brain tumor committee under the bold leadership of Dr. Amar Gajjar. With the consortium co-leadership of clinical trialist Maryam Fouladi and the accountability to DIPG patients and their family, this program is moving unexpectedly quickly towards its goal," says Charles Keller, MD, Associate Professor and leader of the Pediatric Cancer Biology Program, Pape' Family Pediatric Research Institute in the Department of Pediatrics at Oregon Health & Science University.
"If we succeed, it will be because families that have donated their children's tumor gave us this opportunity. We are reminded every day that the cultures we study are parent-directed Legacy Gifts of the most selfless kind from children who current therapy could not save (the brain stem being vital to life; therefore, tumor donation can only occur at autopsy). What ABC2
, CureSearch for Children's Cancer, the Lyla Nsouli Foundation, and The Cure Starts Now have done to make our consortium possible, and so quickly, is unprecedented – and greatly appreciated," adds Dr. Keller.
The research project entitled, "Rapid Preclinical Development of a Targeted Therapy Combination for DIPG" was launched with initial support from The Cure Starts Now Foundation. Two additional European labs were added to the project with funding from The Lyla Nsouli Foundation for Children's Brain Cancer Research (based in London, UK).
The funding from ABC2
and CureSearch for Children's Cancer added a cutting-edge functional genomics component that will prioritize potential new drug targets. "We are proud to support this multi-national team of researchers in their efforts to rapidly develop effective drugs to treat children suffering from DIPG," said Max Wallace, CEO of ABC2
. "By combining forces with our non-profit partners, ABC2
looks forward to leveraging the resources and expertise of all the organizations to improve the lives of children with cancer." John Lehr, president and CEO of CureSearch for Children's Cancer echoed Wallace's comments saying that "developing new drug targets is an integral step to providing children with DIPG a better prognosis. CureSearch is committed to funding research in rare cancer types so that one day, all children will be guaranteed a cure." Keith Desserich, Chairman and Co-Founder of The Cure Starts Now Foundation added, "innovative strategies such as Dr. Keller's and his collaborators will help lead to a revolution in cancer care for all. Not only by focusing on rare cancers like DIPG can we offer hope to children fighting this disease, but we also learn vital skills that may ultimately lead to a cure for all cancers; and in this way, this may be the start of a truly homerun strategy in cancer cures."
About the DIPG Preclinical Consortium
The multi-national consortium is identifying potentially important biological pathways in DIPGs that are readily targetable with currently available molecularly-targeted agents. In addition, the consortium has successfully grown human DIPG tumors from autopsy materials in the petri dish and has developed mouse models of DIPG – a key resource to functionally testing potential therapies.
Since the number of children with this unfortunate disease is limited, and the number of available targeted agents is quite large, the consortiumhypothesizes that it can identify a promising combination of molecularly-targeted agents using functional genomics to prioritize targets. The ultimate goal is to move the most effective single agent or combination therapy forward to early phase clinical trials in the next 18-24 months.
The DIPG Preclinical Consortium team includes:
Charles Keller MD, Kellie Nazemi MD and Nate Selden MD, PhD at Oregon Health & Science University
Oren Becher MD, Duke University Medical Center
Michelle Monje MD, PhD, Stanford University
Maryam Fouladi MD, Cincinnati Children's Hospital Medical Center
Cynthia Hawkins, MD, PhD, University of Toronto
Xiao-Nan Li MD, PhD, Baylor College of Medicine
Dannis G. van Vuurden MD, MSc, & Esther Hulleman, VU Cancer Center Amsterdam
Jacques Grill, Institut Gustave-Roussy, Villejuif, France
For More Information about the Research Funding Partners:
Accelerate Brain Cancer Cure: www.abc2.org
CureSearch for Children's Cancer: www.curesearch.org
The Cure Starts Now Foundation: www.curestartsnow.org
The Lyla Nsouli Foundation for Children's Brain Cancer Research: www.lylansoulifoundation.org
Dr. Mark Souweidane Performs Successful DIPG Biopsy
On Friday, January 6, Dr. Mark Souweidane performed a DIPG biopsy on Olivia Boccuzzi, who was only 22 months old when she was diagnosed with the disease on September 21 of last year. Olivia's parents, Enza and Frank, noticed their daughter had a hard time walking and her face was starting to droop. They decided to take her to the emergency room, where the terrible news was confirmed by an MRI. This beautiful young girl who loves dancing like a ballerina, watching Dora the Explorer and playing with 4-year-old brother James, now faced six weeks of radiation and a regimen of Dexamethasone (brand name Decadron), a steroid drug frequently administered to brain stem tumor patients for the swelling and "tightness" of their tumor at the base of their skull. Doctors treating Olivia continued to monitor her until, on December 8, an MRI showed that Olivia's tumor exhibited a significant amount of necrosis. With these atypical results, her parents consulted with Dr. Mark Souweidane, who agreed to perform the biopsy. This procedure had been done in France but remains a controversial choice in the United States. The operation was a success and after one night in the ICU, Olivia is back home with her family awaiting the results of her groundbreaking biopsy. The Cristian Rivera Foundation wishes to applaud Olivia and her family for their strength and bravery in the face of DIPG and will keep them in our thoughts and prayers as Olivia continues to recover.
Community comes out to support 5-year-old cancer patient
By Katie Sullivan email@example.com
She doesn't know Zach Cadwalder or have any affiliation with his family, but when Jessica Kane heard about the fundraiser that will benefit the sick 5-year-old, she knew she wanted to be a part of it.
"I'm a teacher, and it's terrible to see a child sick. So, anything you can do," she said.
Ms. Kane was one of hundreds who came out to support the Cadwalders after the Green Ridge family found out in November that Zach had diffuse intrinsic pontine glioma - an inoperable brain tumor. The family takes Zach to an experimental clinical trial at the National Institutes of Health in Maryland for treatment.
Family and friends pulled together to make sure the family had what they needed to get by.
"It's devastating news; he really is the strongest person we know," said relative Gabrielle Kasaczun, who helped organize the event. "We decided we had to do something to raise money."
With a large picture of Zach dressed in a purple baseball uniform - his ears poking out from his cap, clutching a bat and flashing a toothy grin - displayed in the middle of St. Mary's Center on Friday night, hundreds of people came to eat, drink and buy raffle tickets.
The proceeds go toward the young boy's medical care and travel expenses as Zach undergoes radiation and chemotherapy five days a week. His family said his attitude is as positive as ever.
"He's very brave. He's happy and outgoing," Ms. Kasaczun said of her little cousin.
Zach's aunt, Lauren Washo, said the family can only be grateful for the overwhelming support shown for the 5-year-old.
"He's our superhero," Ms. Washo said.
Ms. Kane said working with children as a pre-kindergarten teacher has shown her a lot about the spirit of young kids like Zach.
"They have a wonderful ability to bounce back," she said. "They have an inner strength you wish adults had sometimes."
Contact the writer: firstname.lastname@example.org
Milestone Clinical Trial for DIPG Approved
Dr. Mark Souweidane, Director of Pediatric Neurological Surgery, has received FDA approval for a clinical trial for young patients diagnosed with Diffuse Intrinsic Pontine Glioma (DIPG). Dr. Souweidane is the Principal Investigator on the clinical trial, which will use a novel surgical technique (convection-enhanced delivery, or CED) to deliver a tumor-fighting agent directly to the site of the glioma, bypassing the blood-brain barrier that prevents most drugs from reaching these deadly brain stem cancers in children.
The trial will use CED to deliver a therapeutic agent called 124I-8H9 directly to the tumor site using a surgically placed infusion cannula. The agent consists of the 8H9 antibody, which is produced by mice and has been shown to attack many kinds of tumors, combined with the radioactive substance 124I. In studies on other kinds of cancer, 124I-8H9 has delivered a one-two punch, with 8H9 binding to the tumor and 124I killing the cancer cells with radiation. The procedure has been tested safely in animals, but this clinical trial is the first time CED has been used to administer 124I-8H9 to a human brain.
Initial patients will be treated with a small dose of 124I-8H9 and monitored for side effects. As the study progresses, new patients will be treated with increasing doses as Dr. Souweidane monitors the safety and effectiveness of each dosage. The study is expected to last for one to two years, with a minimum of 12 DIPG patients between the ages of 3 and 21 enrolled and monitored.
Dr. Souweidane has been working on DIPG research for more than a decade, and preparing for this clinical trial for much of that time. His dedication to finding hope for his patients has been unswerving, and this trial represents an enormous leap forward in DIPG research.
"This trial is about renewed hope," says Dr. Souweidane. "It's a departure from the standard, ineffective, therapy, and has the potential to create a whole new paradigm in brain tumor treatment. Delivering drugs intravenously hasn't worked because of the blood-brain barrier - to get even a small amount of medicine to the tumor we need high doses of chemotherapy, which is toxic to the rest of the body. But placing the agent outside the blood vessels, directly into the tumor, greatly reduces that toxicity while maximizing the attack on the tumor itself."
This new approach represents a ray of hope for families facing the diagnosis of DIPG. This rare brain tumor has been uniformly fatal, made all the more heartbreaking by its propensity to strike very young children. The tumors are inoperable due to their ill-defined borders as well as their position in the delicate pons area of the brain stem. Radiation has been the standard approach, but it is not a cure and usually extends life only by a short time. Some 200 to 300 children in North America a year die from DIPG - usually within months of their diagnosis.
Unlike other critical diseases of childhood, DIPG has suffered from a lack of funding that has meant a complete lack of progress in survival rates. Over the past few decades, survival rates for medulloblastoma have reached 70 percent; for acute lymphoblastic leukemia the rate is now 85 percent. Over that same time, survival rates for DIPG have remained essentially at zero, as major foundations directed their support toward more common conditions. It is Dr. Souweidane's hope that this innovative clinical trial will be a major first step in creating a survival rate for DIPG for the first time.
Dr. Souweidane has been fortunate to have the support of several organizations and groups whose gifts have provided much-needed funding to help him reach this point. He credits the Dana Foundation, The Cure Starts Now, the Cristian Rivera Foundation, the Beez Foundation, the Matthew Larson Foundation, and St. Baldick's with being instrumental in allowing him to complete the important research needed before this clinical trial could begin.
The DIPG trial will be conducted at both Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical Center, where Dr. Souweidane holds appointments. For more information about the trial, call Dr. Souweidane's office at 212-639-7056, or visit the complete description of the trial on clinicaltrials.gov
The fight of her life
Five-year-old battles brain tumor
By Brian Croce email@example.com
An ever-smiling Valentina has undergone radiation treatments to shrink her brain tumor. She will undergo an MRI on Jan. 12 to check the status of the tumor.
When a person is diagnosed with a serious medical condition at any age it is devastating news for his or her friends and family. But when the parents of a four-year-old receive word that their child has an inoperable brain tumor, it's earth shattering.
Unfortunately, that's exactly what Farmingdale residents Erik and Cristina Bravin were told on July 21. Their daughter, Valentina, was diagnosed with Diffuse Intrinsic Pontine Glioma (DIPG), a tumor located in the middle of the brain stem, leaving the Bravin's with a limited amount of treatment options to explore.
"It's shocking," Cristina said of the diagnosis. "There was a lot of anger and asking 'Why us?" She added, "Nobody ever wants to hear anything negative about their child, let alone when they basically give her a death sentence."
To help the Bravin's with mounting medical and travel expenses, several fundraisers have been held in Valentina's name including one at the Lynbrook VFW last November. Valentina's aunt and uncle, Gina and Frank Orosz of Lynbrook, planned the event. It was attended by approximately 170 people and raised $26,000. There have also been fundraisers held in Valentina's hometown of Farmingdale.
The Bravins didn't waste any time to see what the possible routes of treatment were. "We basically went into search mode," Cristina said. "We were researching every factor and treatment possible around the country and around the world."
Their research led them to Houston, Texas where Valentina underwent 30 radiation treatments for six consecutive weeks at MB Anderson Cancer Center. The procedures started on Aug. 18 and ended Oct. 3.
Valentina, who turned five on New Year's Eve, has been brave throughout her fight with DIPG according to her mom. "She's a fighter," Cristina said. "She doesn't do things willingly, but when she does eventually comply with anything that doctors and nurses have to do she's very tough." Cristina said that the radiation treatment did shrink the tumor by 50 percent, but those results are usually temporary.
The Bravin's were hoping Valentina would be accepted to a trial at Memorial Sloan-Kettering Cancer Center by Jan. 10, but according to Cristina the Food and Drug Administration (FDA) didn't do them any favors.
"We were waiting for the FDA to approve this trial for several months," Cristina said. "They finally approved it on Dec. 29 which didn't leave much time for that cutoff date." She said that Valentina missed the Jan. 10 cutoff by a few days because patients could not be admitted to the trial after 14 weeks since their last radiation treatment.
"It's a life or death situation, but the FDA couldn't care less," she said.
After Valentina's diagnosis, Cristina resigned from her job at Winthrop University Hospital and temporarily moved to Texas while her daughter underwent radiation treatment. Erik works in sales and has also taken a lot of time off in recent months.
Valentina, who likes ballet, ice skating and playing with Barbie dolls, will undergo an MRI on January 12 to check the status of her tumor. If the tumor is stable or has regressed, Cristina said Valentina may be considered for a new trial at the National Institutes of Health in Bethesda, MD.
Valentina's grandfather started a foundation, Friends of Valentina, after the diagnosis. Cristina said the foundation is a medical trust fund to help cover expenses and to give Valentina special celebrations when she feels up to it.
If you would like to donate to or find out more information about Friends of Valentina, you can contact Gina at (516)384-9739 or Frank at (516)509-7862 or firstname.lastname@example.org.
An experimental xenograft mouse model of
diffuse pontine glioma designed for therapeutic testing
J Neurooncol. 2012 Jan 10. [Epub ahead of print]
An experimental xenograft mouse model of diffuse pontine glioma designed for therapeutic testing.
Aoki Y Hashizume R, Ozawa T, Banerjee A, Prados M, James CD, Gupta N.
Department of Neurological Surgery and Brain Tumor Research Center, University of California San Francisco, 505 Parnassus Ave., Rm M779, San Francisco, CA, 94143-0112, USA.
The prognosis for diffuse infiltrating pontine gliomas (DIPG) remains extremely poor, with the majority of patients surviving less than 2 years. Here, we have adapted standard xenograft techniques to study glioma growth in the mouse brainstem, and have utilized the mouse model for studying a relevant therapeutic for treating DIPGs. bioluminescence imaging monitoring revealed a progressive increase in signal following the injection of either of two tumor cell types into the brainstem. Mice with orthotopic GS2 tumors, and receiving a single 100 mg/kg dose of temozolomide showed a lengthy period of decreased tumor luminescence, with substantially increased survival relative to untreated mice (P < 0.001). A small molecule inhibitor that targets cdk4/6 was used to test AM-38 brainstem xenograft response to treatment. Drug treatment resulted in delayed tumor growth, and significantly extended survival. Our results demonstrate the feasibility of using an orthotopic brainstem tumor model in athymic mice, and for application to testing therapeutic agents in treating DIPG.
ALSF Announces 2011 'A' Awards
To Researchers In San Francisco Area
Researchers at Stanford University and the University of California at San Francisco receive prestigious awards to examine childhood cancers
Wynnewood, PA (December 2011) – Alex's Lemonade Stand Foundation for Childhood Cancer (ALSF) today announced the recipients of the 'A' Award, a groundbreaking pediatric cancer research grant designed to jumpstart the careers of promising scientists in the pediatric cancer field. Michelle Monje, MD, PhD of Stanford University and William Gustafson, MD, PhD of the University of California at San Francisco were chosen from nearly 30 applicants as the 2011 recipients of the grant which totals $375,000 over the course of three years. Dr. Monje's research will target Diffuse Intrinsic Pontine Glioma (DIPG) while Dr. Gustafson will examine neuroblastoma.
The 'A' Award joined a prestigious line of medical and nursing grants from Alex's Lemonade Stand Foundation in 2009. The award was created in an effort to find the best and brightest young researchers and encourage them to build life-long careers in the pediatric cancer field. The Foundation believes that young researchers are integral components of finding new treatments and cures, and by providing support for their research these investigators will utilize their talents toward pediatric oncology.
Dr. Monje, an Assistant Professor of Neurology and Neuro-Oncology at Stanford University, will focus her research on DIPG, a highly aggressive and difficult to treat brain tumor. DIPG is the second most common malignant brain tumor in children and the leading cause of pediatric cancer death with a survival time after diagnosis of less than a year. Monje and her team have developed the first published experimental model system to study DIPG and have thus discovered molecular factors that drive tumor growth. Now, they will use this experimental model system to test therapeutic strategies combining two drugs to target both the cells responsible for tumor initiation and those responsible for tumor expansion. If successful, Monje would seek to translate her findings into a clinical trial for children battling DIPG.
Dr. Gustafson will examine high-risk MYCN amplified neuroblastoma, a deadly form of childhood cancer which frequently becomes resistant to chemotherapy and radiation. In his research, Dr. Gustafson will develop models of this high-risk disease for pre-clinical testing, and he will utilize cutting-edge chemistry to direct targeted therapy against the Aurora A protein, known to be critically important both in driving cell growth and in maintaining high MYCN levels. Through these studies, Dr. Gustafson will ultimately work toward novel and clinically tolerable therapies which target drug-resistant neuroblastoma.
Along with the funds provided to 'A' Award recipients, the award will also include access to ALSF's Scientific Advisory Board for periodic consultation and a choice of reference books to enhance the researcher's personal pediatric oncology library. New in 2011, the Foundation will also give recipients the choice of equipment to aid in their research (up to $10,000 value), funding to attend one medical conference of their choice and the opportunity to meet other 'A' Award recipients to collaborate and share ideas.
The 'A' Award will mark the final grants allocated from Alex's Lemonade Stand Foundation for 2011. However, the Foundation will begin accepting applications for its newly announced Bridge Grant program for NIH childhood cancer research applications that received excellent scores but did not receive funding on December 15, 2011. In an effort to keep the projects of these researchers on track while they reapply for funding, ALSF's Bridge Grant will provide $100,000 over a 12 month period. Applications will be taken on a rolling review basis with a deadline of January 9, 2012 or until capacity is reached. A total of three grants will be funded in this cycle, with a second cycle planned for the summer of 2012.
For more information on the 'A' Award, Bridge Grants or Alex's Lemonade Stand Foundation's grant program, visit: www.ALSFGrants.org
Alex's Lemonade Stand Foundation 2011 'A' Award Recipients
Michelle Monje, MD, PhD, Stanford University, Palo Alto, CA
A Combinatorial Approach to Target the Tumor-Initiating and Transit Amplifying Cellular Subpopulations in Diffuse Intrinsic Pontine Glioma (DIPG)
Diffuse Intrinsic Pontine Glioma (DIPG) is the second most common malignant brain tumor in children and the leading cause of pediatric cancer death. We have developed the first published experimental model system to study DIPG, and using this have discovered some of the molecular factors that drive DIPG tumor growth. We now propose to use our mouse model system to test a therapeutic strategy combining two drugs. The purpose of this proposal is to develop a strategy that will target two types of cells in the tumor - those responsible for tumor initiation, and a distinct population responsible for tumor expansion. If efficacious, we would seek to translate the findings quickly to a clinical trial for children suffering from DIPG.
William Gustafson, MD, PhD, University of California San Francisco, San Francisco, CA
Blockade of p53 and Aurora A in Therapy Resistant Neuroblastoma
High-risk MYCN-amplified neuroblastoma is typically responsive to therapy at diagnosis, becoming resistant to chemotherapy/radiation at relapse. Mirroring human disease, the well established TH-MYCN model of neuroblastoma, developed in our lab, is responsive to conventional chemotherapy. To cure MYCN-amplified high-risk neuroblastoma, we propose to: 1) Develop models which accurately reflect the genetics and behavior of relapsed, chemotherapy refractory disease. I have developed a drug-resistant version of the TH-MYCN model by crossing it with models defective in p53, leading to a defective response to chemotherapy, and mirroring a similar defect in resistant childhood disease. I plan to characterize the response of this model to conventional chemotherapy as well as novel, targeted therapies including those subsequently described. 2) Development of novel and clinically tolerable therapies which target drug-resistant neuroblastoma. I propose to use cutting-edge chemistry to direct targeted therapy against the Aurora A protein, known to be critically important both in driving cell growth, and in maintaining high MYCN levels. I have already generated a new class of Aurora A inhibitors which block both Aurora functions (current drugs only block cell growth) which we predict will have improved activity against MYCN amplified neuroblastoma.